Health-Related Quality of Life Outcomes in PARADIGM-HF
Top Cited Papers
- 1 August 2017
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Circulation: Heart Failure
Abstract
Background: Patients with heart failure and reduced ejection fraction have impaired health-related quality of life (HRQL) with variable responses to therapies that target mortality and heart failure hospitalizations. In PARADIGM-HF trial (Prospective Comparison of ARNI [Angiotensin Receptor–Neprilysin Inhibitor] With ACEI [Angiotensin-Converting–Enzyme Inhibitor] to Determine Impact on Global Mortality and Morbidity in Heart Failure), sacubitril/valsartan reduced morbidity and mortality compared with enalapril. Another major treatment goal is to improve HRQL. Given improvements in mortality with sacubitril/valsartan, this analysis provides comprehensive assessment of impact of therapy on HRQL in survivors only. Methods and Results: Patients (after run-in phase) completed disease-specific HRQL using Kansas City Cardiomyopathy Questionnaire (KCCQ) at randomization, 4 month, 8 month, and annual visits. Changes in KCCQ scores were calculated using repeated measures analysis of covariance model that adjusted for treatment and baseline values (principal efficacy prespecified at 8 months). Among the 8399 patients enrolled in PARADIGM-HF, 7623 (91%) completed KCCQ scores at randomization with complete data at 8 months for 6881 patients (90% of baseline). At 8 months, sacubitril/valsartan group noted improvements in both KCCQ clinical summary score (+0.64 versus −0.29; P =0.008) and KCCQ overall summary score (+1.13 versus −0.14; P P =0.01). Adjusted change scores demonstrated consistent improvements in sacubitril/valsartan compared with enalapril through 36 months. Conclusions: Change scores in KCCQ clinical summary scores and KCCQ overall summary scores were better in patients treated with sacubitril/valsartan compared with those treated with enalapril, with consistency in most domains, and persist during follow-up beyond 8 months. These findings demonstrate that sacubitril/valsartan leads to better HRQL in surviving patients with heart failure. Clinical Trial Registration: URL: http://www.c linicalt rials.gov . Unique identifier: NCT01035255.This publication has 28 references indexed in Scilit:
- Angiotensin–Neprilysin Inhibition versus Enalapril in Heart FailureThe New England Journal of Medicine, 2014
- Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin‐converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM‐HF)European Journal of Heart Failure, 2013
- Assessing the Impact of Heart Failure Therapeutics on Quality of Life and Functional CapacityCurrent Treatment Options in Cardiovascular Medicine, 2013
- Heart FailureJACC: Heart Failure, 2013
- Heart rate reduction with ivabradine and health related quality of life in patients with chronic heart failure: results from the SHIFT studyEuropean Heart Journal, 2011
- Assessment of quality of life in severe heart failure.Current Heart Failure Reports, 2007
- Comparison of losartan and captopril on heart failure–related outcomes and symptoms from the losartan heart failure survival study (ELITE II)American Heart Journal, 2005
- Effect of Valsartan on Quality of Life When Added to Usual Therapy for Heart Failure: Results From The Valsartan Heart Failure TrialJournal of Cardiac Failure, 2005
- Prognostic Value of Health Status in Patients With Heart Failure After Acute Myocardial InfarctionCirculation, 2004
- Preferences for quality of life or survival expressed by patients with heart failureThe Journal of Heart and Lung Transplantation, 2001